Rapid Novor Inc

Rapid Novor Inc. is the world's leader in antibody sequencing, discovery and characterization. We provide pre-clinical R&D analytical services to biotech, pharmaceutical and diagnostic companies around the world, to help them speed up discovery. Our unique expertise lies in mass spectrometry based sequencing of both monoclonal and polyclonal antibodies. Our patented technology gives us unmatched speed, accuracy and confidence, which has lead to 10,000+ successful projects since 2015.

Our unique polyclonal antibody sequencing technology has unlocked a powerful method for antibody discovery. By sequencing the functional, stable and abundant antibodies in immunoserum, we avoid costly and time-consuming 'trial and error' from b-cell based or computational approaches. After hundreds of projects, we boast an incredibly high success rate in discovering fit-for-purpose antibodies that are highly specific.

Rapid Novor's offerings include epitope mapping, polyclonal epitope mapping, and epitope scanning using a variety of orthogonal techniques such as HDX-MS, XL-MS and peptide scanning. We also offer Surface Plasmon Resonance (SPR) analysis for true binding affinity and kinetic analysis. Finally, we offer LC-MS based antibody characterization.

The company's mission is to advance life science for better human health with next generation protein sequencing.

For more information, visit www.rapidnovor.com. Follow the company on Twitter @rapidnovor.